Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Novartis has claimed a first-in-class regulatory approval in the US for oral BTK inhibitor remibrutinib as a second-line treatment for chronic spontaneous urticaria (CSU), also known as chronic hives.

Around nearly every corner of the health and wellness space is a reminder to increase your fiber intake—this makes sense, as most Americans aren’t getting nearly enough. And the industry has quickly ...